Reduced-dose apixaban in cancer-associated thrombosis: a single-center experience

Pol Arch Intern Med. 2023 Dec 21;133(12):16609. doi: 10.20452/pamw.16609. Epub 2023 Nov 20.

Authors

Anna Werońska¹, Anetta Undas^{2

3}, Ewa Wypasek⁴

Affiliations

¹ Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, Kraków, Poland
² Department of Thromboembolic Disorders, Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland
³ St. John Paul II Hospital, Kraków, Poland
⁴ Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, Kraków, Poland; St. John Paul II Hospital, Kraków, Poland. e.wypasek@szpitaljp2.krakow.pl

PMID: 37987610
DOI: 10.20452/pamw.16609

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anticoagulants
Humans
Neoplasms* / complications
Neoplasms* / drug therapy
Pyrazoles / therapeutic use
Pyridones / therapeutic use
Thrombosis* / drug therapy
Thrombosis* / etiology

Substances

apixaban
Anticoagulants
Pyrazoles
Pyridones